Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests may reveal hidden heart damage after attack

NCT ID NCT02823886

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at 21 people who had a heart attack to see if markers of inflammation in the blood are linked to the amount of heart damage seen on MRI scans. Researchers measured inflammation levels at several time points and compared them to MRI images taken a week later. The goal was to better understand the body's inflammatory response after a heart attack and how it relates to recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict heart damage and recovery after a heart attack using simple blood tests.
What could go wrong
This is a small, early study with only 21 people, so results may not apply to everyone. It is designed to gather knowledge, not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Jan 2017

Finished

Jul 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients, aged over 18, without any legal protection measure, * Having a health coverage, * Presenting within 12 hours of the onset of chest pain, * Who have ST segment elevation ≥0.2 millivolt (mV) in two contiguous leads, * For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI). * he culprit coronary artery has to be the left anterior descending (LAD) or the right coronary (RC) * The LAD or RC artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography. * Preliminary oral informed consent followed by signed informed consent as soon as possible * Final TIMI ≥ 2 Exclusion Criteria: * Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis). * Patients with cardiogenic shock * Patient in Cardiac arrest * History of Myocardial Infarction * Contre-indication to MRI : claustrophobia, pacemaker or cardiac defibrillator , eye metal body allergy to gadolinium * Patient with Atrial Fibrillation. * Patients with loss of consciousness or (Glasgow \<14) * known renal insufficiency (either known creatinin clearance \< 30 ml/min/1.73m² or current medical care for severe renal insufficiency) * Patients with any disorder associated with immunological dysfunction * Adult with legal protection measure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

Contacts and locations

Locations

  • Hospices Civils de Lyon

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.